Palvella Therapeutics Inc... (PVLA)
NASDAQ: PVLA
· Real-Time Price · USD
49.76
2.46 (5.20%)
At close: Aug 18, 2025, 3:59 PM
49.55
-0.41%
After-hours: Aug 18, 2025, 05:31 PM EDT
5.20% (1D)
Bid | 49.51 |
Market Cap | 550.08M |
Revenue (ttm) | 53K |
Net Income (ttm) | -17.2M |
EPS (ttm) | -2.53 |
PE Ratio (ttm) | -19.67 |
Forward PE | -13.51 |
Analyst | Buy |
Ask | 50.33 |
Volume | 154,340 |
Avg. Volume (20D) | 134,793 |
Open | 48.00 |
Previous Close | 47.30 |
Day's Range | 46.43 - 50.17 |
52-Week Range | 11.17 - 50.17 |
Beta | -0.01 |
About PVLA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PVLA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PVLA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 months ago
-15.72%
Palvella Therapeutics shares are trading lower on ...
Unlock content with
Pro Subscription
6 months ago
+6.26%
Palvella Therapeutics shares are trading higher after TD Cowen initiated coverage on the stock with a Buy rating and announced a price target of $44.

1 week ago · https://thefly.com
Palvella Therapeutics initiated with an Outperform at Raymond JamesRaymond James initiated coverage of Palvella Therapeutics with an Outperform rating and $54 price target. The firm says the company is developing Qtorin rapamycin, a novel topical therapy designed to ...